-
公开(公告)号：US09561219B2
公开(公告)日：2017-02-07
申请号：US14985408
申请日：2015-12-31
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Liang Liu , Jingrong Wang
IPC: A61K31/4725 , A61K31/4745 , A61K31/4748
CPC classification number: A61K31/4745 , A61K31/4725 , A61K31/4748
Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.
-
公开(公告)号：US09119847B2
公开(公告)日：2015-09-01
申请号：US14562780
申请日：2014-12-08
Applicant: Macau University of Science and Technology
Inventor： Yuen Kwan Law , Kam Wai Wong , Liang Liu
IPC: A61K31/4725 , A61K36/185
CPC classification number: A61K31/4725 , A61K36/62
Abstract: The present invention discloses a method of treating neurodegenerative disorder comprising administering an effective amount of an alkaloid which is a bisbenzylisoquinline alkaloid isolated from the traditional Chinese medicinal herb Nelumbo nucifera. The pharmaceutical composition thereof for treating Huntington's disease is also disclosed.
Abstract translation: 本发明公开了一种治疗神经变性疾病的方法，包括给予有效量的生物碱，所述生物碱是从中草药Nelumbo Nucumera分离的双苄基异喹啉生物碱。 还公开了其用于治疗亨廷顿病的药物组合物。
-
13.发明申请公开(公告)号：US20180085413A1
公开(公告)日：2018-03-29
申请号：US15280136
申请日：2016-09-29
Applicant: Macau University of Science and Technology
Inventor： Yuen Kwan Law , Kam Wai Wong , An Gao Wu , Liang Liu , Zeng Wu
IPC: A61K36/25 , A61K31/704 , A61K31/56
CPC classification number: A61K36/25 , A61K31/19 , A61K31/56 , A61K31/704 , A61K2236/33 , A61K2236/35 , A61K2236/39 , A61P25/28
Abstract: A method for treating a subject suffering from a neurodegenerative disease includes administering at least one triterpenoid which can be obtained from Hedera helix. A method for treating a subject suffering from a neurodegenerative disease includes administering an effective amount of a Hedera helix extract which comprises the triterpenoid. The neurodegenerative disease is preferably but not exclusively Parkinson's disease or Huntington's disease. Methods for extracting the triterpenoid from Hedera helix and a method for inducing autophagy in cells by contacting them with the triterpenoid are also provided. The triterpenoid allows an exceptional induction of autophagy, in particular a significant reduction of the protein level of mutant huntingtin, a significant reduction of the protein level of A53T α-synuclein, a significant inhibition of the oligomerization of α-synuclein and a significant inhibition of the inclusion formation of huntingtin via the AMPK-mTOR dependent autophagy inducing pathway.
-
公开(公告)号：US20170151212A1
公开(公告)日：2017-06-01
申请号：US14953860
申请日：2015-11-30
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Thomas Efferth , Onat Kadioglu , Liang Liu
IPC: A61K31/352 , A61K31/337 , A61K31/704
CPC classification number: A61K31/352 , A61K31/337 , A61K31/704 , A61K2300/00
Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant.Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.
-
Patent Agency Ranking
公开(公告)号：US20170128394A1
公开(公告)日：2017-05-11
申请号：US14971153
申请日：2015-12-16
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Thomas Efferth , Su-Wei Xu , Sami Hamdoun , Liang Liu
IPC: A61K31/19 , A61K31/553 , A61K31/704 , A61K31/7048 , A61K31/337 , A61K33/24
CPC classification number: A61K31/19 , A61K31/337 , A61K31/553 , A61K31/704 , A61K31/7048 , A61K33/24 , A61K2300/00
Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.
-
16.发明授权Group of alkaloids, the novel autophagic enhancers for treatment of cancers and neurodegenerative conditions thereof 有权生物碱组，用于治疗癌症的新型自噬增强剂及其神经变性病症公开(公告)号：US09561220B2
公开(公告)日：2017-02-07
申请号：US14985414
申请日：2015-12-31
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Liang Liu , Jingrong Wang
IPC: A61K31/4745 , A61K31/4725 , A61K31/4748
CPC classification number: A61K31/4745 , A61K31/4725 , A61K31/4748
Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.
Abstract translation: 本发明公开了一种治疗癌症的方法，该方法包括给予有效量的生物碱，其中生物碱为留丝氨酸，依沙星碱，屈酸，去甲肾上腺素，栀子或沙利度胺，并从中药中分离出来。 还公开了使用生物碱治疗神经变性疾病。
-
公开(公告)号：US20160106734A1
公开(公告)日：2016-04-21
申请号：US14985420
申请日：2015-12-31
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Liang Liu , Jingrong Wang
IPC: A61K31/4748 , A61K31/4725
CPC classification number: A61K31/4745 , A61K31/4725 , A61K31/4748
Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.
-
公开(公告)号：US20160106729A1
公开(公告)日：2016-04-21
申请号：US14985408
申请日：2015-12-31
Applicant: Macau University of Science and Technology
Inventor： Kam Wai Wong , Yuen Kwan Law , Liang Liu , Jingrong Wang
IPC: A61K31/4725
CPC classification number: A61K31/4745 , A61K31/4725 , A61K31/4748
Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.
-
公开(公告)号：US09005677B2
公开(公告)日：2015-04-14
申请号：US14231671
申请日：2014-03-31
Applicant: Macau University of Science and Technology
Inventor： Yuen Kwan Law , An Guo Wu , Kam Wai Wong , Liang Liu
CPC classification number: A61K36/69 , A61K31/704
Abstract: Use and application of Onjisaponin B derived and isolated from Radix Polygalae as novel autophagy enhancer are provided. A method of preventing, treating and/or delaying the onset of neurodegenerative diseases comprising administering an effective amount of Onjisaponin B is also provided.
Abstract translation: 本发明提供了从根部提取和分离的Onjisaponin B作为新的自噬增强剂的应用和应用。 还提供了预防，治疗和/或延缓神经变性疾病发作的方法，包括给予有效量的Onjisaponin B.
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.023 seconds)
